Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER II

Trial Profile

A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER II

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Hidradenitis suppurativa
  • Focus Registrational; Therapeutic Use
  • Acronyms PIONEER II
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 02 Apr 2021 Results assessing Baseline and week 12 plasma samples from the PIONEER studies were used to assess the levels of circulating proteins by multiplex assays and enzyme linked immunosorbent assays published in the British Journal of Dermatology
    • 24 Dec 2019 Results of post hoc analysis of PIONEER 1 and 2 individual patient data evaluating the efficacy of adalimumab versus placebo using the International Hidradenitis Suppurativa Severity Score System (IHS4) published in the Journal of the American Academy of Dermatology
    • 27 Mar 2019 Results evaluating the optimal medium-term adalimumab maintenance dosing strategy in moderate-to-severe HS using PIONEER I and PIONEER II trials published in the British Journal of Dermatology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top